Products

Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Human HER2 /ErbB2 (23-450) Protein, Fc Tag, 10x100 µg  

Recombinant Human HER2 /ErbB2 (23-450) Protein, Fc Tag, 10x100 µg

Recombinant Human Her2 / ErbB2 Protein, Thr 23 - Ile 450, produced in human 293 cells (HEK293), Fc Tag

Synonym: recombinant, human protein ERBB2, CD340,HER-2, HER2, MLN19, NEU, NGL, TKR1

More details

HE2-H525x-1K

Availability: within 7 days

2 400,00 €

Background
Human Epidermal growth factor Receptor 2 (HER2) is also called ERBB2, HER-2,HER-2 /neu, NEU, NGL,TKR1 and c-erb B2,and is a protein giving higher aggressiveness in breast cancers. It is a member of the ErbB protein family, more commonly known as the epidermal growth factor receptor family. HER2 is a cell membrane surface-bound receptor tyrosine kinase and is normally involved in the signal transduction pathways leading to cell growth and differentiation. HER2 is thought to be an orphan receptor, with none of the EGF family of ligands able to activate it. Approximately 30% of breast cancers have an amplification of the HER2 gene or overexpression of its protein product. Overexpression of this receptor in breast cancer is associated with increased disease recurrence and worse prognosis. HER2 appears to play roles in development, cancer, communication at the neuromuscular junction and regulation of cell growth and differentiation .

Source
Recombinant Human Her2 (23-450), Fc Tag (HE2-H525x) is expressed from human 293 cells (HEK293). It contains AA Thr 23 - Ile 450 (Accession # P04626-1).
Predicted N-terminus: Thr 23

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus. The protein has a calculated MW of 74.5 kDa. The protein migrates as 95-100 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Human Her2 (23-450), Fc Tag does not contain Herceptin MAb binding domain.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

Reconstitution
See Certificate of Analysis for reconstitution instructions and specific concentrations.

Storage
Avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C); After reconstitution under sterile conditions for 3 months (-70°C). 

Bioactivity
n/a

References


(1) Kanai, Y. et. al., 1995, Biochem. Biophys. Res. Commun.208:1067.
(2) Codony-Seeervat, J. et al., 1999, Cancer Res. 59: 1196-1201.
(3) Tzahar, E. et al., 1998, Biochim. Biophys. Acta. 1377: 25-37.
(4) Kermit, L. et al, 1999, J. Biol. Chem. 274: 5263-5266.
(5) Hellyer, N.J. et. al., 2001, J. Biol. Chem. 276:42153.
(6) Daly, R.J., 1999, Growth Factors 16:255.